- On-Demand
Making the Right Call: Biomarker Testing and Targeting in NSCLC: Part I: Equitable, Guideline-based Testing for Prognosis and Treatment
- Credit: 0.30hr(s)
- AAPA, CME, CPE, NCPD
- November 29, 2022 —
- November 28, 2023
- Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
- Specialties: Biomarkers, NSCLC
- Location: Internet Activity Enduring
In the past decade, advances in non-small cell lung cancer (NSCLC) have rapidly evolved with the discovery of targetable mutations and subsequent therapies. However, suboptimal biomarker testing practices and varying adherence to testing guidelines presents a challenge to implementing targeted treatment. Are you ready to test your skills against those of your colleagues? Join us for Part 1 of this question and answer based educational activity Equitable, Guideline-based Testing for Prognosis and Treatment where our oncology experts will:
Review guideline recommendations for biomarker testing and treatment selection
Present clinical evidence for the use of current and emerging targeted therapies
Discuss health disparities in biomarker testing